Company intelligence / Profile preview

Infraredx

Bedford or Burlington, Massachusetts, United Statesinfraredx.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Infraredx’s IVUS+NIRS platform has demonstrated clinical utility in identifying lipid-rich plaques and guiding interventional cardiology procedures. The YELLOW III Study showed that 26 weeks of Evolocumab reduced lipid core burden index and plaque volume as measured by the company’s system.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Medical Imaging

Partnerships

Nipro Corporation (acquirer/distribution/manufacturing partner)B. Braun Medical, Inc. (clinical study collaboration)Deutsches Herzzentrum Berlin (academic clinical collaborator)

Beyond the preview

Go deeper on Infraredx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infraredx.

Explore the full profile